In this retrospective analysis involving individuals with CKD and albuminuria, combination therapy with SGLT2 inhibitors and finerenone (vs. SGLT2 inhibitors monotherapy or finerenone monotherapy) was well-tolerated and resulted in a significant reduction in albuminuria, demonstrating their synergistic effect. The gene discussed is SLC5A2; the disease is chronic kidney disease.